中文

拓尔思 Revenue Breakdown

Period 2026-06-30 ・ Reported 2026-08-29

拓尔思 reported revenue of ¥0.13B for the period ended 2026-06-30, -48.4% year on year. Net income was ¥-0.17B, a -135.1% net margin on a 61.4% gross margin. The largest revenue line is 人工智能软件产品及服务 at 45% of the total. Free cash flow for the period was ¥-0.05B.

ItemAmountY/Y
Revenue¥0.13B-48.4%
Gross profit¥0.08B
Operating income¥-0.17B
Net income¥-0.17B
Gross margin61.4%Net margin -135.1%
Revenue Q/Q-6.8%

Revenue Segments

SegmentRevenueShare
人工智能软件产品及服务¥0.06B44.6%
大数据软件产品及服务¥0.04B31.4%
安全产品¥0.02B12.5%
系统集成及其他¥0.01B11.6%

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.05B38.6%
R&D¥0.06B46.0%
SG&A¥0.18B146.2%
Tax & other¥-0.00B-2.4%

Balance sheet & cash flow

ItemAmount
Total assets¥3.98B
Total liabilities¥0.30B
Shareholders' equity¥3.68B
Equity / assets92.5%
Operating cash flow¥-0.03B
Capital expenditure¥0.02B
Free cash flow¥-0.05B
Cash conversion (OCF / net income)51%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

永利股份银信科技洲明科技金城医药开尔新材方直科技上海新阳ST美晨冠昊生物东宝生物飞力达瑞丰光电

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies